Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Pharma Frontiers
8 min read
RET Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
RET is a validated precision-oncology target with meaningful remaining development space, especially in resistance and earlier lines.
Pharma Pioneer
8 min read
ALK Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
ALK is a high-validation, high-competition target. MCP-derived evidence supports continued strategic interest, but only with clear differentiation.
Latest Hotspot
8 min read
FGFR2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual FGFR2 target evaluation report for cholangiocarcinoma, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Latest Hotspot
8 min read
CD38 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual CD38 target evaluation report for multiple myeloma, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Pharma Frontiers
8 min read
CD47 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual CD47 target evaluation report for AML, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Pharma Frontiers
8 min read
CD20 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual CD20 target evaluation report for non-Hodgkin lymphoma, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Pharma Frontiers
8 min read
CD19 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual CD19 target evaluation report for B-ALL, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Pharma Frontiers
8 min read
BCMA Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual BCMA target evaluation report for multiple myeloma, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Pharma Pioneer
8 min read
DLL3 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual DLL3 target evaluation report for SCLC, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Pharma Pioneer
8 min read
Nectin-4 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual Nectin-4 target evaluation report for urothelial carcinoma, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Hot Spotlight
8 min read
MSLN Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual MSLN target evaluation report for ovarian cancer, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Hot Spotlight
8 min read
B7-H3 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual B7-H3 target evaluation report for NSCLC, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.